X

PULMOXYL-250 CAPSULE 250mg

Product Information

Registration Status: Active

SIN09602P

PULMOXYL-250 CAPSULE 250mg is approved to be sold in Singapore with effective from 1998-06-01. It is marketed by NAINA MOHAMED & SONS PTE LTD, with the registration number of SIN09602P.

This product contains Amoxycillin 250mg in the form of CAPSULE. It is approved for ORAL use.

This product is manufactured by Micro Labs LTD in INDIA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

A broad-spectrum semisynthetic antibiotic similar to ampicillin except that its resistance to gastric acid permits higher serum levels with oral administration. Amoxicillin is commonly prescribed with clauvanic acid (a beta lactamase inhibitor) as it is susceptible to beta-lacatamase degradation.

Indication

For the treatment of infections of the ear, nose, and throat, the genitourinary tract, the skin and skin structure, and the lower respiratory tract due to susceptible (only b-lactamase-negative) strains of Streptococcus spp. (a- and b-hemolytic strains only), S. pneumoniae, Staphylococcus spp., H. influenzae, E. coli, P. mirabilis, or E. faecalis. Also for the treatment of acute, uncomplicated gonorrhea (ano-genital and urethral infections) due to N. gonorrhoeae (males and females).

Mechanism of Action

Amoxicillin binds to penicillin-binding protein 1A (PBP-1A) located inside the bacterial cell well. Penicillins acylate the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation of the enzyme prevents the formation of a cross-link of two linear peptidoglycan strands, inhibiting the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that amoxicllin interferes with an autolysin inhibitor.

Pharmacokinetics

Absorption
Rapidly absorbed after oral administration.
Distribution
Metabolism
Hepatic metabolism accounts for less than 30% of the biotransformation of most penicillins
Elimination

Toxicity

Serious toxicity is unlikely following large doses of amoxicillin. Acute ingestion of large doses of amoxicillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses.

Active Ingredient/Synonyms

(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | 6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid | Amox | Amoxicilina | Amoxicillin (anhydrous) | Amoxicillin anhydrous | Amoxicilline | Amoxicillinum | Amoxycillin | AX | p-Hydroxyampicillin | α-amino-p-hydroxybenzylpenicillin | Amoxicillin |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!